Fda Broadens Afatinib

FDA Ðại afatinib signs to previously untreated, metastatic NSCLC other EGFR mutation not subject

Love Later Life

FDA Ðại afatinib signs to previously untreated, metastatic NSCLC other EGFR mutation not subject

Love Later Life

FDA D.I.S.C.O.: FDA approval of cabozantinib for hepatocellular carcinoma

U.S. Food and Drug Administration

FDA Gives Green Light to Biogen's Alzheimer’s Drug

Bloomberg Television

FDA to broaden access for nonprescription meds

FDA D.I.S.C.O. Burst Edition: FDA approvals of Imbruvica (ibrutinib) for pediatric patients with ...

U.S. Food and Drug Administration

Jim Cramer on FDA resignations connected to the approval of Biogen’s Alzheimer’s drug

CNBC Television

FDA D.I.S.C.O. Burst Edition: FDA approval of Tafinlar (dabrafenib) in combination with Mekinist ...

U.S. Food and Drug Administration

FDA D.I.S.C.O. Burst Edition: FDA approval of Tafinlar (dabrafenib) with Mekinist (trametinib) fo...

U.S. Food and Drug Administration

FDA D.I.S.C.O. Burst Edition: FDA approval of Keytruda (pembrolizumab) for the adjuvant treatment...

U.S. Food and Drug Administration

FDA D.I.S.C.O. Burst Edition: FDA approval of Fruzaqla (fruquintinib) for adult patients with met...

U.S. Food and Drug Administration

FDA approves controversial Biogen Alzheimer's drug | DW News

FDA's Friedman on Reliable Manufacturing Processes

INTERPHEXEvents

FDA D.I.S.C.O. Burst Edition: FDA approval of Cabometyx (cabozantinib) for locally advanced or me...

U.S. Food and Drug Administration

FDA Approval of Adjuvant Dabrafenib/Trametinib in BRAF+ Melanoma

The FDA Has Approved Aducanumab (Aduhelm™). Now What?

FDA D.I.S.C.O. Burst Edition: FDA approval of Imfinzi (durvalumab) for adult patients with locall...

U.S. Food and Drug Administration

FDA D.I.S.C.O. Burst Edition: FDA approval of Augtyro (repotrectinib) for locally advanced or met...

U.S. Food and Drug Administration

FDA D.I.S.C.O. Burst Edition: FDA approval of Keytruda (pembrolizumab) as adjuvant treatment for ...

U.S. Food and Drug Administration

First new drug for Alzheimer's in 20 years approved by FDA